达雷妥尤单抗联合来那度胺和地塞米松治疗复发或复发/难治性多发性骨髓瘤患者的持久疗效和耐受性（GEN503）：一项开放标签的1/2期研究的最终结果 - Suppr

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

作者信息

Plesner Torben, Arkenau Hendrik-Tobias, Gay Francesca, Minnema Monique C, Boccadoro Mario, Moreau Philippe, Cavenagh Jamie, Perrot Aurore, Laubach Jacob P, Krejcik Jakub, Ahmadi Tahamtan, de Boer Carla, Chen Diana, Chiu Christopher, Schecter Jordan M, Richardson Paul G

机构信息

Vejle Hospital and University of Southern Denmark, Vejle, Denmark.

Sarah Cannon Research Institute, University College London Cancer Institute, London, United Kingdom.

出版信息

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31.

DOI:10.1111/bjh.15879

PMID:30931524

Abstract

摘要

相似文献

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0.

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Am J Hematol. 2019 Dec;94(12):E319-E322. doi: 10.1002/ajh.25633. Epub 2019 Oct 4.

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.

Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11.

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

引用本文的文献

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.

Pharmaceuticals (Basel). 2025 Jan 22;18(2):145. doi: 10.3390/ph18020145.

Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.

Life (Basel). 2024 Mar 15;14(3):389. doi: 10.3390/life14030389.

Epstein-Barr Virus Driven Hodgkin's Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma.

Case Rep Hematol. 2023 Dec 18;2023:6669174. doi: 10.1155/2023/6669174. eCollection 2023.

Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.

Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.

Stem Cell Res Ther. 2021 Mar 25;12(1):211. doi: 10.1186/s13287-021-02277-x.

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.

Pharmaceuticals (Basel). 2020 Nov 27;13(12):426. doi: 10.3390/ph13120426.

Blood Cancer J. 2020 Nov 4;10(11):113. doi: 10.1038/s41408-020-00379-y.

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy.

Cancer Manag Res. 2020 Aug 26;12:7891-7903. doi: 10.2147/CMAR.S212526. eCollection 2020.

Daratumumab in untreated newly diagnosed multiple myeloma.

Ther Adv Hematol. 2019 Dec 23;10:2040620719894871. doi: 10.1177/2040620719894871. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

作者信息

机构信息

Vejle Hospital and University of Southern Denmark, Vejle, Denmark.

Sarah Cannon Research Institute, University College London Cancer Institute, London, United Kingdom.

出版信息

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31.

DOI:10.1111/bjh.15879

PMID:30931524

Abstract

摘要

相似文献

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0.

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Am J Hematol. 2019 Dec;94(12):E319-E322. doi: 10.1002/ajh.25633. Epub 2019 Oct 4.

Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11.

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

引用本文的文献

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.

Pharmaceuticals (Basel). 2025 Jan 22;18(2):145. doi: 10.3390/ph18020145.

Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.

Life (Basel). 2024 Mar 15;14(3):389. doi: 10.3390/life14030389.

Epstein-Barr Virus Driven Hodgkin's Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma.

Case Rep Hematol. 2023 Dec 18;2023:6669174. doi: 10.1155/2023/6669174. eCollection 2023.

Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.

Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.

Stem Cell Res Ther. 2021 Mar 25;12(1):211. doi: 10.1186/s13287-021-02277-x.

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.

Pharmaceuticals (Basel). 2020 Nov 27;13(12):426. doi: 10.3390/ph13120426.

Blood Cancer J. 2020 Nov 4;10(11):113. doi: 10.1038/s41408-020-00379-y.

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy.

Cancer Manag Res. 2020 Aug 26;12:7891-7903. doi: 10.2147/CMAR.S212526. eCollection 2020.

Daratumumab in untreated newly diagnosed multiple myeloma.

Ther Adv Hematol. 2019 Dec 23;10:2040620719894871. doi: 10.1177/2040620719894871. eCollection 2019.

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献